At a recent Pfizer-sponsored symposium, held in conjunction with the 17th Urological Association of Asia Congress at Kuala Lumpur Convention Centre, Professor Bannakij Lojanapiwat gave a lecture on the pathophysiology and management of overactive bladder (OAB) and lower urinary tract symptoms (LUTS), highlighting the importance of individualised pharmacological intervention in optimizing patient outcomes.
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.
At a Duopharma-sponsored symposium during the Diabetes Asia Conference 2019 at Hotel Istana, Kuala Lumpur, Professor Dato’ Dr Mafauzy Mohamed spoke about the role of biosimilar insulin glargine in improving access to diabetes treatment, presenting important evidence that affirms the quality, efficacy and safety of the biosimilar product.
The latest research, clinical data and innovations in
ophthalmology were presented at the 2019 Annual Meeting of the American Academy
of Ophthalmology (AAO) in San Francisco, USA, held on 12−15 October 2019. As in
previous years, an international panel of renowned ophthalmologists attended
the meeting and contributed articles to Eye on AAO 2019 – an e-Bulletin series featuring
research highlights and hot topics presented at the meeting, with commentaries
on their relevance to clinical practice in the Asia Pacific and Latin American regions.
At a recent Boehringer Ingelheim-sponsored symposium held in conjunction with the 10th Malaysian Endocrine and Metabolic Society Annual Congress, two distinguished speakers spoke on the latest updates in glucose-lowering therapy for the treatment for type 2 diabetes mellitus (T2DM) and highlighted some important cardiovascular outcome trial results of these antidiabetic agents.
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.